Study on the Correlation Between the Gene Polymorphisms of CYP2C19, POR and ABCC2 and the Plasma Concentration of Voriconazole in Patients with Invasive Fungal Infections

Expand
  • 1.Kunming Medical University, Yunnan Kunming 650244, China;
    2.Pharmacy Department, Kunming First People′s Hospital, Yunnan Kunming 650244, China

Received date: 2025-07-11

  Revised date: 2025-08-19

  Accepted date: 2025-11-27

  Online published: 2025-12-15

Abstract

Objective: To investigate the impact of genetic polymorphisms of CYP2C19, POR, and ABCC2 on the trough plasma concentration (cmin) of voriconazole (VRZ) in patients with invasive fungal infection (IFI). Methods: Peripheral blood samples from IFI patients were prospectively collected. The plasma concentration of VRZ was determined using two-dimensional liquid chromatography. Simultaneously, polymerase chain reaction was employed to detect the genetic polymorphisms of CYP219 rs4244285, CYP219 rs4986893, POR rs10954732, and ABCC2 rs717620. The correlation between each genotype and the VRZ plasma concentration was then analyzed. Results: A total of 55 plasma samples of the steady-state trough plasma concentration of voriconazole in IFI patients were enrolled in this study. The analysis revealed that at the CYP2C19 rs4244285 locus, the VRZ cmin value in patients with the GG genotype was significantly lower than that in A allele carriers (P<0.05). Similarly, at the CYP2C19 rs4986893 locus, the VRZ cmin value in patients with the GG genotype was markedly lower than that in A allele carriers (P<0.05). At the ABCC2 rs717620 locus, the VRZ cmin value in patients with the CC genotype was significantly lower than that in T allele carriers (P<0.05). However, no significant correlation was observed between the POR rs10954732 locus and the VRZ cmin value in IFI patients (P>0.05). There were significant differences in VRZ cmin among IFI patients with different CYP2C19 metabolic distributions (P<0.01). After stratification based on CYP2C19 metabolic distribution, the influence of the genetic polymorphisms of POR rs10954732 and ABCC2 rs717620 on VRZ cmin in IFI patients did not reach statistical significance. Conclusions: Carriers of the T allele of ABCC2 rs717620 can increase the plasma concentration of VRZ. In the metabolic distribution of CYP2C19, the minimum steady-state concentration of VRZ in PMs patients is higher than that in EMs and IMs patients. After classifying the metabolic distribution of CYP2C19, the gene polymorphisms of POR rs10954732 and ABCC2 rs717620 have no effect on the VRZ cmin in patients with invasive fungal infection.

Cite this article

LI Yaxuan, LI Xingde, WANG Guohui, MAO Panpan, ZHANG Hanshu, LU Saijuan, SONG Cangsang . Study on the Correlation Between the Gene Polymorphisms of CYP2C19, POR and ABCC2 and the Plasma Concentration of Voriconazole in Patients with Invasive Fungal Infections[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(5) : 345 -345-350 . DOI: magtech-2025-07-11-00003

References

     [1] Sanguinetti M, Posteraro B, Beigelman-Aubry C, et al. Diagnosis and treatment of invasive fungal infections: looking ahead [J]. J Antimicrob Chemother, 2019, 74(Suppl 2): ii27-ii37.
     [2] Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations [J]. Infection Drug Resistance, 2016, 9: 291-300.
     [3] 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J]. 临床医学研究与实践,2017,2(20):201.
     [4] 毛盼盼,杜一民,张阳,等.伏立康唑预防HSCT术后侵袭性真菌感染疗效及安全性的Meta分析[J]. 大理大学学报,2017,2(2):31-36.
     [5] Takesue Y, Hanai Y, Oda K, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring [J]. Clin Ther, 2022, 44(12): 1604-1623.
     [6] Moriyama B, Obeng AO, Barbarino J, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy [J]. Clin Pharmacol Ther, 2017, 102(1): 45-51.
     [7] Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society [J]. Therapeutic Drug Monitoring, 2018, 40(6): 663-674.
     [8] 周丽娟,桑智慧,李慧红,等.CYP2C19基因多态性联合C-反应蛋白指导伏立康唑在血液病患者合并侵袭性真菌感染防治中的应用[J]. 中国新药杂志,2024,33(22):2352-2358.
     [9] Berge M, Guillemain R, Trégouet DA, et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients [J]. European J Clin Pharmacol, 2011, 67(3): 253-260.
     [10] Wang T, Zhu H, Sun J, et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections [J]. Intern J Antimicrobial Agents, 2014, 44(5): 436-42.
     [11] Shirasaka Y, Chaudhry AS, McDonald M, et al. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content [J]. Pharmacogenomics J, 2016, 16(4): 375-387.
     [12] Dermauw W, Van Leeuwen T. The ABC gene family in arthropods: comparative genomics and role in insecticide transport and resistance [J]. Insect Biochemistry Molecular Biol, 2014, 45: 89-110.
     [13] 李雅暄,李兴德,王国徽,等.基因多态性对侵袭性真菌感染患者伏立康唑血药浓度影响的Meta分析[J]. 中国药房,2025,36(2):225-231.
     [14] Shi Y, Xiang P, Li L, et al. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population [J]. Forensic Science Intern, 2011, 207(1-3): 183-187.
     [15] Zeng G, Wang L, Shi L, et al. Variability of voriconazole concentrations in patients with hematopoietic stem cell transplantation and hematological malignancies: influence of loading dose, procalcitonin, and pregnane X receptor polymorphisms [J]. European J Clin Pharmacol, 2020, 76(4): 515-523.
     [16] Chen L, Zheng C, Hao M, et al. Association of ABCC2 polymorphism with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention [J]. Front Pharmacol, 2022, 13:889473.
     [17] Allegra S, Fatiguso G, De Francia S, et al. Pharmacogenetic of voriconazole antifungal agent in pediatric patients [J]. Pharmacogenomics, 2018, 19(11): 913-925.
     [18] Zeng G, Shi L, Li H, et al. Effect of cyclosporine a and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation [J]. Xenobiotica, 2020, 50(5): 614-619.
     [19] 王霖霖. 药物基因组学与肾功能对伏立康唑稳态谷浓度的影响研究 [D]. 中南大学, 2024.
Outlines

/

[an error occurred while processing this directive]